Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Chemical Biology

Abstract PR16: A druggable transcriptional vulnerability in NRF2-dependent lung cancer

Liron Bar-Peled, Esther Kemper and Benjamin Cravatt
Liron Bar-Peled
The Scripps Research Institute, La Jolla, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Kemper
The Scripps Research Institute, La Jolla, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin Cravatt
The Scripps Research Institute, La Jolla, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-8514.SYNTHLETH-PR16 Published October 2017
  • Article
  • Info & Metrics
Loading
Abstracts: AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; January 4-7, 2017; San Diego, CA

Abstract

The b-ZIP transcription factor NRF2 is a master regulator of the cellular antioxidant response and frequently activated in Non-Small Cell Lung Cancers (NSCLCs). While direct pharmacological inhibition of NRF2 has proven challenging, its aberrant activation rewires metabolic and signaling networks in cancer cells that may create special vulnerabilities for therapeutic intervention. Here, we use chemical proteomics to map ligandable proteins in NRF2-activated NSCLC cells, leading to the discovery of metabolic and transcriptional pathways that are strictly regulated by NRF2. Principal among these was the orphan nuclear receptor NR0B1, which we show nucleates a multimeric protein complex required for the transcriptional output and anchorage-independent growth of NRF2-driven cancers. We further identify small-molecules that target a conserved cysteine within NR0B1's protein interaction domain and show that these chemical probes disrupt NR0B1 complexes and NRF2-dependent cancer cell growth. Our findings thus designate NR0B1 as a druggable, transcriptional co-dependency target for NRF2-activated lung cancers.

Citation Format: Liron Bar-Peled, Esther Kemper, Benjamin Cravatt. A druggable transcriptional vulnerability in NRF2-dependent lung cancer [abstract]. In: Proceedings of the AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; Jan 4-7, 2017; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2017;16(10 Suppl):Abstract nr PR16.

  • ©2017 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Therapeutics: 16 (10 Supplement)
October 2017
Volume 16, Issue 10 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract PR16: A druggable transcriptional vulnerability in NRF2-dependent lung cancer
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract PR16: A druggable transcriptional vulnerability in NRF2-dependent lung cancer
Liron Bar-Peled, Esther Kemper and Benjamin Cravatt
Mol Cancer Ther October 1 2017 (16) (10 Supplement) PR16; DOI: 10.1158/1538-8514.SYNTHLETH-PR16

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract PR16: A druggable transcriptional vulnerability in NRF2-dependent lung cancer
Liron Bar-Peled, Esther Kemper and Benjamin Cravatt
Mol Cancer Ther October 1 2017 (16) (10 Supplement) PR16; DOI: 10.1158/1538-8514.SYNTHLETH-PR16
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Chemical Biology

  • Abstract B39: Small Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA Deficient Cancers
  • Abstract B37: Targeting the energy generation triangle to achieve synthetic lethality for treatment of hepatocellular carcinoma
Show more Chemical Biology

Chemical Biology: Oral Presentations - Proffered Abstracts

  • Abstract B39: Small Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA Deficient Cancers
  • Abstract B37: Targeting the energy generation triangle to achieve synthetic lethality for treatment of hepatocellular carcinoma
  • Abstract PR16: A druggable transcriptional vulnerability in NRF2-dependent lung cancer
Show more Chemical Biology: Oral Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement